This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Insufficient understanding of the completeness of dementia diagnosis and for whom in Medicare claims data limits their use. This study analyzes prevalence and incidence of dementia in survey and claims data to understand differences.
RCMAR Scientist Reginald Tucker-Seeley presents a model to consistently measure financial hardship to better inform cancer prevention research identify connections between socioeconomic circumstances and cancer risk-related behaviors and cancer screening among older adults.
Jacobson and Alpert studied more than 2.4 million monthly claims for chemotherapy treatment and found little impact on outpatient chemotherapy treatment for the majority of oncology drugs identified as experiencing shortages between 2004 and 2011.